Merus to Present at the Canaccord Genuity 45th Annual Growth Conference
Merus (NASDAQ: MRUS), a company specializing in oncology and developing innovative multispecific antibodies and antibody drug conjugates, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference. Bill Lundberg, M.D., the company's President and CEO, will engage in a fireside chat on Wednesday, August 13, 2025, at 1:30 p.m. ET.
The presentation will be available via webcast on the Investors section of Merus's website, with an archived version accessible for a limited time following the event.
Merus (NASDAQ: MRUS), un'azienda specializzata in oncologia e nello sviluppo di anticorpi multispecifici innovativi e coniugati anticorpo-farmaco, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Crescita di Canaccord Genuity. Bill Lundberg, M.D., Presidente e CEO dell'azienda, parteciperà a una conversazione informale il mercoledì 13 agosto 2025 alle 13:30 ET.
La presentazione sarà disponibile in webcast nella sezione Investitori del sito web di Merus, con una versione archiviata accessibile per un periodo limitato dopo l'evento.
Merus (NASDAQ: MRUS), una empresa especializada en oncología y en el desarrollo de anticuerpos multispecíficos innovadores y conjugados anticuerpo-fármaco, ha anunciado su participación en la 45ª Conferencia Anual de Crecimiento de Canaccord Genuity. Bill Lundberg, M.D., presidente y CEO de la empresa, participará en una charla informal el miércoles 13 de agosto de 2025 a la 1:30 p.m. ET.
La presentación estará disponible vía webcast en la sección de Inversionistas del sitio web de Merus, con una versión archivada accesible por tiempo limitado después del evento.
Merus (NASDAQ: MRUS)는 종양학 전문 기업으로 혁신적인 다중특이성 항체 및 항체-약물 접합체를 개발하고 있으며, Canaccord Genuity 제45회 연례 성장 컨퍼런스에 참여한다고 발표했습니다. 회사의 사장 겸 CEO인 Bill Lundberg, M.D.가 2025년 8월 13일 수요일 오후 1시 30분(동부시간)에 화상 대화에 참여할 예정입니다.
발표 내용은 Merus 웹사이트의 투자자 섹션에서 웹캐스트로 제공되며, 행사 후 일정 기간 동안 아카이브 버전도 이용할 수 있습니다.
Merus (NASDAQ : MRUS), une entreprise spécialisée en oncologie et développant des anticorps multispecifiques innovants ainsi que des conjugués anticorps-médicament, a annoncé sa participation à la 45e conférence annuelle de croissance de Canaccord Genuity. Bill Lundberg, M.D., président et PDG de la société, participera à une discussion informelle le mercredi 13 août 2025 à 13h30 ET.
La présentation sera disponible en webcast dans la section Investisseurs du site web de Merus, avec une version archivée accessible pendant une durée limitée après l'événement.
Merus (NASDAQ: MRUS), ein Unternehmen, das sich auf Onkologie spezialisiert hat und innovative multispezifische Antikörper sowie Antikörper-Wirkstoff-Konjugate entwickelt, hat seine Teilnahme an der 45. jährlichen Wachstums-Konferenz von Canaccord Genuity angekündigt. Bill Lundberg, M.D., Präsident und CEO des Unternehmens, wird am Mittwoch, den 13. August 2025, um 13:30 Uhr ET an einem Kamin-Gespräch teilnehmen.
Die Präsentation wird als Webcast im Investor-Bereich der Merus-Website verfügbar sein, mit einer archivierten Version, die für eine begrenzte Zeit nach der Veranstaltung abrufbar ist.
- None.
- None.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at 1:30 p.m. ET.
The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.
About Merus
Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, LinkedIn and Bluesky.
Multiclonics®, Biclonics®, Triclonics® and ADClonics® are registered trademarks of Merus N.V.
Investor and Media Inquiries:
Sherri Spear
Merus N.V.
SVP Investor Relations and Strategic Communications
617-821-3246
s.spear@merus.nl
Kathleen Farren
Merus N.V.
Director IR/Corp Comms
617-230-4165
k.farren@merus.nl
FAQ
When is Merus (MRUS) presenting at the Canaccord Genuity Growth Conference 2025?
Who will represent Merus (MRUS) at the Canaccord Genuity Conference?
How can investors access Merus's (MRUS) presentation at the Canaccord Conference?
What type of company is Merus (MRUS)?
